Therapeutic Response Statement (Sensitivity)

This therapeutic response statement supports the relationship that NPM1 p.W288Cfs*12 status confers therapeutic sensitivity to Revumenib in patients with Acute Leukemias of Ambiguous Lineage.

This statement is based on a regulatory approval from the Food and Drug Administration:

REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.

Citation

Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf. Revised October 2025. Accessed December 26, 2025.